IL6 and hepatocellular carcinoma: The cut-off value described in our study is in the range of previously reported cut-off values for IL-6 to detect survival benefit of HCC patients who underwent transarterial chemoembolization (10 pg/mL) and radioembolization (6.53 pg/mL) (Jang et al. 2012; Seidensticker et al. 2017).